312 related articles for article (PubMed ID: 22388760)
1. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.
Seol H; Lee HJ; Choi Y; Lee HE; Kim YJ; Kim JH; Kang E; Kim SW; Park SY
Mod Pathol; 2012 Jul; 25(7):938-48. PubMed ID: 22388760
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab.
Lee HJ; Kim JY; Park SY; Park IA; Song IH; Yu JH; Ahn JH; Gong G
Am J Clin Pathol; 2015 Oct; 144(4):570-8. PubMed ID: 26386078
[TBL] [Abstract][Full Text] [Related]
3. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.
Lee HJ; Seo AN; Kim EJ; Jang MH; Suh KJ; Ryu HS; Kim YJ; Kim JH; Im SA; Gong G; Jung KH; Park IA; Park SY
Am J Clin Pathol; 2014 Dec; 142(6):755-66. PubMed ID: 25389328
[TBL] [Abstract][Full Text] [Related]
4. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.
Brunelli M; Manfrin E; Martignoni G; Miller K; Remo A; Reghellin D; Bersani S; Gobbo S; Eccher A; Chilosi M; Bonetti F
Am J Clin Pathol; 2009 May; 131(5):678-82. PubMed ID: 19369627
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of HER2 gene amplification according to stage of breast cancer.
Kim YS; Won YS; Park KS; Song BJ; Kim JS; Oh SJ; Jeon HM; Jung SS; Park WC
J Korean Med Sci; 2008 Jun; 23(3):414-20. PubMed ID: 18583876
[TBL] [Abstract][Full Text] [Related]
6. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma.
Yoon HH; Shi Q; Sukov WR; Lewis MA; Sattler CA; Wiktor AE; Wu TT; Diasio RB; Jenkins RB; Sinicrope FA
J Clin Oncol; 2012 Nov; 30(32):3932-8. PubMed ID: 22987085
[TBL] [Abstract][Full Text] [Related]
7. Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan.
Chen JR; Hsieh TY; Chen HY; Yeh KY; Chen KS; ChangChien YC; Pintye M; Chang LC; Hwang CC; Chien HP; Hsu YC
Virchows Arch; 2014 Jun; 464(6):689-99. PubMed ID: 24756215
[TBL] [Abstract][Full Text] [Related]
8. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.
Lamy PJ; Fina F; Bascoul-Mollevi C; Laberenne AC; Martin PM; Ouafik L; Jacot W
Breast Cancer Res; 2011 Feb; 13(1):R15. PubMed ID: 21288332
[TBL] [Abstract][Full Text] [Related]
9. HER2 genetic heterogeneity in breast carcinoma.
Ohlschlegel C; Zahel K; Kradolfer D; Hell M; Jochum W
J Clin Pathol; 2011 Dec; 64(12):1112-6. PubMed ID: 22011446
[TBL] [Abstract][Full Text] [Related]
10. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
[TBL] [Abstract][Full Text] [Related]
11. Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.
Ercolani C; Marchiò C; Di Benedetto A; Fabi A; Perracchio L; Vici P; Sperati F; Buglioni S; Arena V; Pescarmona E; Sapino A; Terrenato I; Mottolese M
J Exp Clin Cancer Res; 2017 Oct; 36(1):143. PubMed ID: 29029640
[TBL] [Abstract][Full Text] [Related]
12. HER2 gene copy number and breast cancer-specific survival.
Biserni GB; Engstrøm MJ; Bofin AM
Histopathology; 2016 Nov; 69(5):871-879. PubMed ID: 27271096
[TBL] [Abstract][Full Text] [Related]
13. Reply to 'Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance'.
Lee HJ; Park SY
Mod Pathol; 2013 Apr; 26(4):610-1. PubMed ID: 23542524
[No Abstract] [Full Text] [Related]
14. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.
Sneige N; Hess KR; Multani AS; Gong Y; Ibrahim NK
Cancer; 2017 Apr; 123(7):1115-1123. PubMed ID: 27893937
[TBL] [Abstract][Full Text] [Related]
15. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma.
Jang M; Kim E; Choi Y; Lee H; Kim Y; Kim J; Kang E; Kim SW; Kim I; Park S
Breast Cancer Res; 2012 Aug; 14(4):R115. PubMed ID: 22863309
[TBL] [Abstract][Full Text] [Related]
16. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy.
Bose S; Mohammed M; Shintaku P; Rao PN
Breast J; 2001; 7(5):337-44. PubMed ID: 11906444
[TBL] [Abstract][Full Text] [Related]
17. Pathologic Features and Clinical Implications of Breast Cancer With HER2 Intratumoral Genetic Heterogeneity.
Muller KE; Marotti JD; Tafe LJ
Am J Clin Pathol; 2019 Jun; 152(1):7-16. PubMed ID: 30892594
[TBL] [Abstract][Full Text] [Related]
18. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines.
Vance GH; Barry TS; Bloom KJ; Fitzgibbons PL; Hicks DG; Jenkins RB; Persons DL; Tubbs RR; Hammond ME;
Arch Pathol Lab Med; 2009 Apr; 133(4):611-2. PubMed ID: 19391661
[TBL] [Abstract][Full Text] [Related]
19. Equivocal (HER2 IHC 2+) breast carcinomas: gene-protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits.
Pekar G; Kasselaki I; Pekar-Lukacs A; Dekany C; Hellberg D; Tot T
Histopathology; 2019 Jan; 74(2):300-310. PubMed ID: 30113715
[TBL] [Abstract][Full Text] [Related]
20. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
Hanna WM; Rüschoff J; Bilous M; Coudry RA; Dowsett M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
Mod Pathol; 2014 Jan; 27(1):4-18. PubMed ID: 23807776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]